Under this agreement, Sangamo will provide a non-exclusive, worldwide license to Open Monoclonal Technologies (OMT) for the commercial use of transgenic animals generated using Sangamo’s proprietary zinc finger DNA-binding protein (ZFP) technology.
OMT will pay Sangamo an upfront license fee, payments upon the achievement of certain clinical development milestones, a share of payments received by OMT from sublicensees, and royalties on sales of any products developed using Sangamo’s ZFP technology. For any given OMT Product, OMT has the right to buy out its future royalty payment obligations under the agreement by paying a lump sum fee to Sangamo.
Philip Gregory, vice president of research at Sangamo, said: “Our ZFP Nuclease platform addresses a major problem that has long hampered the development of transgenic models in species other than mice. The frequency and precision of ZFN-mediated genome editing, in combination with the ability to design ZFNs against potentially any gene, opens up the potential to more easily generate transgenic animals of any species.”